OBJECTIVE: To investigate the presence and clinical significance of anti-Scl-70 antibodies in patients with systemic lupus erythematosus (SLE). METHODS: Levels of antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM). RESULTS: Of 128 consecutive SLE patients, 25% were positive for anti-Scl-70 antibody; this antibody activity was cognate in nature. No SLE patient could be classified as also having systemic sclerosis. The levels of anti-Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755-0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti-Scl-70 and anti-double-stranded DNA antibodies (r = 0.558, P < 0.001). Patients with anti-Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. CONCLUSION: Anti-Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.
OBJECTIVE: To investigate the presence and clinical significance of anti-Scl-70 antibodies in patients with systemic lupus erythematosus (SLE). METHODS: Levels of antibodies against Scl-70 were determined by a commercial clinical enzyme-linked immunosorbent assay (ELISA) during routine evaluation. Results were verified by an additional ELISA with a characterized bovine Scl-70, by ELISA with a recombinant human topoisomerase I, by Western blot, and by double diffusion in agar gel. Disease activity was estimated retrospectively by the Systemic Lupus Activity Measure (SLAM). RESULTS: Of 128 consecutive SLEpatients, 25% were positive for anti-Scl-70 antibody; this antibody activity was cognate in nature. No SLEpatient could be classified as also having systemic sclerosis. The levels of anti-Scl-70 were significantly correlated with the SLAM score for the entire cohort (r = 0.563, P < 0.001) and for 7 individual patients with multiple longitudinal measurements (r = 0.755-0.951, P < 0.001; n = 6) (r = 0.378, P < 0.05; n = 1). A significant correlation was also found between the levels of anti-Scl-70 and anti-double-stranded DNA antibodies (r = 0.558, P < 0.001). Patients with anti-Scl-70 had significantly higher risk of pulmonary hypertension (P < 0.01) and renal involvement (P < 0.001) than patients without this antibody. CONCLUSION: Anti-Scl-70 antibody is present in a significant subset of patients with SLE. For this subset, it offers a good correlate of disease activity and suggests increased risk for pulmonary hypertension and nephritis.
Authors: D Villalta; N Bizzaro; S Platzgummer; A Antico; M Tampoia; L Camogliano; D Bassetti; M Pradella; A Piazza; F Manoni; R Tozzoli; E Tonutti Journal: Clin Rheumatol Date: 2004-12-10 Impact factor: 2.980
Authors: Mohamed A Hamidou; Marie A Audrain; Agathe Masseau; Christian Agard; Anne Moreau Journal: Clin Rheumatol Date: 2006-03-07 Impact factor: 2.980
Authors: Minoru Satoh; Malgorzata E Krzyszczak; Yi Li; Angela Ceribelli; Steven J Ross; Edward K L Chan; Mark S Segal; Michael R Bubb; Eric S Sobel; Westley H Reeves Journal: Arthritis Res Ther Date: 2011-05-10 Impact factor: 5.156
Authors: Guillermo Barturen; Lorenzo Beretta; Ricard Cervera; Ronald Van Vollenhoven; Marta E Alarcón-Riquelme Journal: Nat Rev Rheumatol Date: 2018-01-24 Impact factor: 20.543
Authors: Malgorzata E Krzyszczak; Yi Li; Steven J Ross; Angela Ceribelli; Edward K L Chan; Michael R Bubb; Eric S Sobel; Westley H Reeves; Minoru Satoh Journal: Clin Rheumatol Date: 2011-04-27 Impact factor: 2.980